| 2024/07/16 16:52:13 | |
|---|---|
| Price | |
| 3.542 EUR | |
| Difference | 5.04% (0.17) |
General attributes
| ISIN | FR0004056851 |
| Symbol | VLA |
| Exchange | Stuttgart |
| Currency | EUR |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 959 EUR |
| Benchmark | CAC 40 INDEX |
Market data
| Bid (Bid size) | - (0) |
| Ask (Ask size) | - (0) |
| Open | 3.39 EUR |
| High | 3.542 EUR |
| Low | 3.388 EUR |
| Close (prev. day) | 3.372 EUR |
| VWAP | - |
| Volume (pcs) | 6,120 |
| Trading volume | 21,110.44 |
| Number of trades | 6 |
| Last size | 100 |
Futures and Options
| Related Futures | - |
| Related Options | - |
PDF Downloads
| Company report: VALNEVA SE |  |
Add Benchmark:
Recent research
| Date | Headline | Download | |
| 2024/07/12 |
|
Global Equity Ratings |
|
| 2024/06/21 |
|
Global Equity Ratings |
|
| 2024/06/14 |
|
Global Equity Ratings |
|
| 2024/05/29 |
|
Global Equity Ratings |
|
| 2024/04/26 |
|
Global Equity Ratings |
|
| 2024/07/16 16:52:13 | |
|---|---|
| Price | |
| 3.542 EUR | |
| Difference | 5.04% (0.17) |
General attributes
| ISIN | FR0004056851 |
| Symbol | VLA |
| Exchange | Stuttgart |
| Currency | EUR |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 959 EUR |
| Benchmark | CAC 40 INDEX |
Market data
| Bid (Bid size) | - (0) |
| Ask (Ask size) | - (0) |
| Open | 3.39 EUR |
| High | 3.542 EUR |
| Low | 3.388 EUR |
| Close (prev. day) | 3.372 EUR |
| VWAP | - |
| Volume (pcs) | 6,120 |
| Trading volume | 21,110.44 |
| Number of trades | 6 |
| Last size | 100 |
Performance and Risk
| 6m | 1Y | 3Y | |
| Perf (%) | -22.25% | -51.43% | -68.78% |
| Perf (abs.) | -0.97 | -3.57 | -7.43 |
| Beta | 1.42 | 1.30 | 1.06 |
| Volatility | 55.10 | 49.06 | 86.93 |
Add Benchmark:
Price data
| Ø price 5 days | Ø volume 5 days (pcs.) | 3.324 EUR (974) |
| Ø price 30 days | Ø volume 30 days (pcs.) | 3.416 EUR (1,162) |
| Ø price 100 days | Ø volume 100 days (pcs.) | 3.541 EUR (2,493) |
| Ø price 250 days | Ø volume 250 days (pcs.) | 4.616 EUR (1,639) |
| YTD High | date | 4.995 EUR (2024/01/09) |
| YTD Low | date | 2.969 EUR (2024/03/06) |
| 52 Weeks High | date | 7.100 EUR (2023/11/10) |
| 52 Weeks Low | date | 2.969 EUR (2024/03/06) |
All listings for VALNEVA SE
| Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
| Xetra | 2024/07/16 | 17:35 | 3.46 EUR | 0.04 | 28 |
| Vienna Stock Exchange | 2024/07/16 | 15:30 | 3.434 EUR | 0.00 | 4 |
| Tradegate | 2024/07/16 | 18:23 | 3.508 EUR | 0.14 | 58 |
| Stuttgart | 2024/07/16 | 16:52 | 3.542 EUR | 0.02 | 6 |
| Munich | 2024/07/16 | 08:08 | 3.392 EUR | 0.00 | 1 |
| London Stock Exchange | 2024/05/02 | 17:57 | 3.40 EUR | 0.03 | 1 |
| Hanover | 2024/07/16 | 08:48 | 3.396 EUR | 0.00 | 1 |
| Hamburg | 2024/07/16 | 08:21 | 3.382 EUR | 0.00 | 1 |
| Frankfurt | 2024/07/16 | 18:04 | 3.55 EUR | 0.01 | 5 |
| FINRA other OTC Issues | 2024/07/12 | 16:44 | 3.70 USD | 0.00 | 1 |
| Euronext Paris | 2024/07/16 | 17:35 | 3.494 EUR | 1.48 | 813 |
| Euronext Milan MTF Trading After Hours | - | - | - | 0.00 | - |
| Duesseldorf | 2024/07/16 | 16:31 | 3.476 EUR | 0.00 | 4 |
| Berlin | 2024/07/16 | 08:08 | 3.372 EUR | 0.00 | 1 |
Company Logo
Contact Details
| VALNEVA SE |
| - - |
| Campus Bio-Ouest, 6, rue Alain Bombard - 44800 Saint-Herblain |
| Telefon: +33-2-28-07-37-10 |
| Fax: + |
| E-mail: info@valneva.com |
PDF Downloads
| Company report: VALNEVA SE | |
Company Profile
Valneva SE is a specialty vaccine company, which focuses on the development, manufacturing, and commercialization of prophylactic vaccines for infectious diseases. It operates through the following segments: Commercialized Products, COVID, Vaccine Candidates, and Technologies and Services. The Commercialized Products segment markets vaccines, currently IXIARO and DUKORAL vaccines, as well as third-party products. The COVID segment develops, manufactures, and distribute related to COVID-19 vaccine candidate, VLA2001. The Vaccine Candidates segment focuses on proprietary research and development programs aiming to generate new approvable products to generate future cash flows from product sales or from commercialization through partnering with pharmaceutical companies. The Technologies and Services segment offers services and inventions at a commercialization stage. The company was founded on April 7, 1999 and is headquartered in Saint-Herblain, France. |
Members of Management Board
| Thomas Lingelbach | Chairman of Managing Board |
| Dipal Patel | Member of Executive Committee |
| Franck Grimaud | Member of Executive Committee |
| Frederic Jacotot | Member of Executive Committee |
| Juan Carlos Jaramillo | Member of Executive Committee |
| Peter Bühler | Member of Executive Committee |
| Petra Pesendorfer | Member of Executive Committee |
| Vincent Dequenne | Member of Executive Committee |
Board of directors
| Anne-Marie Graffin | Chairman of Supervisory Board |
| Kathrin Jansen | Member of Supervisory Board |
| Danièle Guyot-Caparros | Member of Supervisory Board |
| James Connolly | Member of Supervisory Board |
| James Sulat | Member of Supervisory Board |
| Maïlys Ferrère | Member of Supervisory Board |